Post-Marketing Surveillance of Adalimumab in Korean Hidradenitis Suppurativa Subjects

CompletedOBSERVATIONAL
Enrollment

17

Participants

Timeline

Start Date

March 10, 2017

Primary Completion Date

July 31, 2019

Study Completion Date

July 31, 2019

Conditions
Hidradenitis Suppurativa (HS)
Trial Locations (19)

13496

CHA Bundang Medical center, CHA University /ID# 203364, Seongnam-si

13620

Seoul National Univ Bundang ho /ID# 202254, Seongnam

16499

Ajou University Hospital /ID# 163243, Suwon

41944

Kyungpook National Univ Hosp /ID# 162930, Daegu

49201

Dong-A University Hospital /ID# 162931, Busan

61469

Chonnam National University Hospital /ID# 162932, Gwangju

03722

Yonsei University Health System, Severance Hospital /ID# 162933, Seodaemun-gu

04597

Seoul SongDo Hospital /ID# 202597, Seoul

06273

Gangnam Severance Hospital /ID# 162924, Seoul

06351

Samsung Medical Center /ID# 162934, Seoul

06591

St. Mary's Hospital of the Cat /ID# 162923, Seoul

02841

Korea University Anam Hospital /ID# 162922, Seoul

03080

Seoul National University Hospital /ID# 162935, Seoul

04763

Hangyang University Medical Ce /ID# 162929, Seoul

05030

Konkuk University Medical Cent /ID# 162927, Seoul

05505

Asan Medical Center /ID# 162925, Seoul

07441

Hallym University Kangnam Sacred Heart Hospital /ID# 162926, Seoul

07985

Ewha Womans University Mokdong /ID# 162928, Seoul

100-799

National Medical Center /ID# 162936, Seoul

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AbbVie

INDUSTRY